Bioactive glass in the treatment of ulcerative colitis to regulate the TLR4 / MyD88 / NF-?B pathway

Ulcerative colitis (UC) is a chronic and recurrent intestinal disease of unknown aetiology, and the few treatments approved for UC have serious side effects. In this study, a new type of uniformly monodispersed calciumenhanced radial mesoporous micro-nano bioactive glass (HCa-MBG) was prepared for UC treatment. We established cellular and rat UC models to explore the effects and mechanism of HCa-MBG and traditional BGs (45S5, 58S) on UC. The results showed that BGs significantly reduced the cellular expression of several inflammatory factors, such as IL-1 & beta;, IL-6, TNF-& alpha; and NO. In the animal experiments, BGs were shown to repair the DSS-damaged colonic mucosa. Moreover, BGs downregulated the mRNA levels of the inflammatory factors IL-1 & beta;, IL-6, TNF-& alpha; and iNOS, which were stimulated by DSS. BGs were also found to manage the expression of key proteins in NF-kB signal pathway. However, HCa-MBG was more effective than traditional BGs in terms of improving UC clinical manifestations and reducing the expression of inflammatory factors in rats. This study confirmed for the first time that BGs can be used as an adjuvant drug in UC treatment, thereby preventing UC progression.

Automated summary

In this study, a new type of calcium-enhanced radial mesoporous micro-nano bioactive glass (HCa-MBG) was found to be more effective than traditional bioactive glasses (BGs) in treating ulcerative colitis (UC). BGs significantly reduced the expression of inflammatory factors and repaired the damaged colonic mucosa in UC models. This study confirmed for the first time that BGs can be used as an adjuvant drug in UC treatment, thereby preventing UC progression.